Robert J Fox1, Paola Raska2, Christian Barro3, Matthew Karafa2, Victoria Konig2, Robert A Bermel1, Marianne Chase4, Christopher S Coffey5, Andrew D Goodman6, Eric C Klawiter4, Robert T Naismith7, Jens Kuhle3. 1. Mellen Center for Multiple Sclerosis, Cleveland Clinic, Cleveland, OH, USA. 2. Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH, USA. 3. Neurologic Clinic and Policlinic, Departments of Medicine, Biomedicine, and Clinical Research, University Hospital Basel, University of Basel, Basel, Switzerland. 4. Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA. 5. University of Iowa, Iowa City, IA, USA. 6. Department of Neurology, University of Rochester, Rochester, NY, USA. 7. Department of Neurology, Washington University, St Louis, MO, USA.
Abstract
BACKGROUND: Sensitive and specific biomarkers for use in progressive multiple sclerosis (MS) have not been established. We investigate neurofilament light (NfL) as a treatment response biomarker in progressive MS. OBJECTIVE: To evaluate whether ibudilast 100 mg/day alters serum and cerebrospinal fluid (CSF) levels of NfL in progressive MS. METHODS: In a protocol-defined exploratory analysis from a 2-year, phase 2 clinical trial of ibudilast in progressive MS (NCT01982942), serum samples were collected from 239 subjects and a subset contributed CSF and assayed using single-molecule assay (SIMOA) immunoassay. A mixed model for repeated measurements yielded log(NfL) as the response variable. RESULTS: The geometric mean baseline serum NfL was 31.9 and 28.8 pg/mL in placebo and ibudilast groups, respectively. The geometric mean baseline CSF NfL was 1150.8 and 1290.3 pg/mL in placebo and ibudilast groups, respectively. Serum and CSF NfL correlations were r = 0.52 and r = 0.78 at weeks 48 and 96, respectively. Over 96 weeks, there was no between-group difference in NfL in either serum (p = 0.76) or CSF (p = 0.46). After controlling for factors that may affect NfL, no effect of ibudilast on NfL in either serum or CSF was observed. CONCLUSION: Ibudilast treatment was not associated with a change in either serum or CSF NfL.
BACKGROUND: Sensitive and specific biomarkers for use in progressive multiple sclerosis (MS) have not been established. We investigate neurofilament light (NfL) as a treatment response biomarker in progressive MS. OBJECTIVE: To evaluate whether ibudilast 100 mg/day alters serum and cerebrospinal fluid (CSF) levels of NfL in progressive MS. METHODS: In a protocol-defined exploratory analysis from a 2-year, phase 2 clinical trial of ibudilast in progressive MS (NCT01982942), serum samples were collected from 239 subjects and a subset contributed CSF and assayed using single-molecule assay (SIMOA) immunoassay. A mixed model for repeated measurements yielded log(NfL) as the response variable. RESULTS: The geometric mean baseline serum NfL was 31.9 and 28.8 pg/mL in placebo and ibudilast groups, respectively. The geometric mean baseline CSF NfL was 1150.8 and 1290.3 pg/mL in placebo and ibudilast groups, respectively. Serum and CSF NfL correlations were r = 0.52 and r = 0.78 at weeks 48 and 96, respectively. Over 96 weeks, there was no between-group difference in NfL in either serum (p = 0.76) or CSF (p = 0.46). After controlling for factors that may affect NfL, no effect of ibudilast on NfL in either serum or CSF was observed. CONCLUSION: Ibudilast treatment was not associated with a change in either serum or CSF NfL.
Authors: Robert J Fox; Christopher S Coffey; Robin Conwit; Merit E Cudkowicz; Trevis Gleason; Andrew Goodman; Eric C Klawiter; Kazuko Matsuda; Michelle McGovern; Robert T Naismith; Akshata Ashokkumar; Janel Barnes; Dixie Ecklund; Elizabeth Klingner; Maxine Koepp; Jeffrey D Long; Sneha Natarajan; Brenda Thornell; Jon Yankey; Robert A Bermel; Josef P Debbins; Xuemei Huang; Patricia Jagodnik; Mark J Lowe; Kunio Nakamura; Sridar Narayanan; Ken E Sakaie; Bhaskar Thoomukuntla; Xiaopeng Zhou; Stephen Krieger; Enrique Alvarez; Michelle Apperson; Khurram Bashir; Bruce A Cohen; Patricia K Coyle; Silvia Delgado; L Dana Dewitt; Angela Flores; Barbara S Giesser; Myla D Goldman; Burk Jubelt; Neil Lava; Sharon G Lynch; Harold Moses; Daniel Ontaneda; Jai S Perumal; Michael Racke; Pavle Repovic; Claire S Riley; Christopher Severson; Shlomo Shinnar; Valerie Suski; Bianca Weinstock-Guttman; Vijayshree Yadav; Aram Zabeti Journal: N Engl J Med Date: 2018-08-30 Impact factor: 91.245
Authors: Michael Khalil; Charlotte E Teunissen; Markus Otto; Fredrik Piehl; Maria Pia Sormani; Thomas Gattringer; Christian Barro; Ludwig Kappos; Manuel Comabella; Franz Fazekas; Axel Petzold; Kaj Blennow; Henrik Zetterberg; Jens Kuhle Journal: Nat Rev Neurol Date: 2018-10 Impact factor: 42.937
Authors: Fred Lublin; David H Miller; Mark S Freedman; Bruce A C Cree; Jerry S Wolinsky; Howard Weiner; Catherine Lubetzki; Hans-Peter Hartung; Xavier Montalban; Bernard M J Uitdehaag; Martin Merschhemke; Bingbing Li; Norman Putzki; Fonda C Liu; Dieter A Häring; Ludwig Kappos Journal: Lancet Date: 2016-01-28 Impact factor: 79.321
Authors: Claire Bridel; Wessel N van Wieringen; Henrik Zetterberg; Betty M Tijms; Charlotte E Teunissen; José C Alvarez-Cermeño; Ulf Andreasson; Markus Axelsson; David C Bäckström; Ales Bartos; Maria Bjerke; Kaj Blennow; Adam Boxer; Lou Brundin; Joachim Burman; Tove Christensen; Lenká Fialová; Lars Forsgren; Jette L Frederiksen; Magnus Gisslén; Elizabeth Gray; Martin Gunnarsson; Sara Hall; Oskar Hansson; Megan K Herbert; Joel Jakobsson; Jan Jessen-Krut; Shorena Janelidze; Gudmundur Johannsson; Michael Jonsson; Ludwig Kappos; Mohsen Khademi; Michael Khalil; Jens Kuhle; Mikael Landén; Ville Leinonen; Giancarlo Logroscino; Ching-Hua Lu; Jan Lycke; Nadia K Magdalinou; Andrea Malaspina; Niklas Mattsson; Lieke H Meeter; Sanjay R Mehta; Signe Modvig; Tomas Olsson; Ross W Paterson; Josué Pérez-Santiago; Fredrik Piehl; Yolande A L Pijnenburg; Okko T Pyykkö; Oskar Ragnarsson; Julio C Rojas; Jeppe Romme Christensen; Linda Sandberg; Carole S Scherling; Jonathan M Schott; Finn T Sellebjerg; Isabella L Simone; Tobias Skillbäck; Morten Stilund; Peter Sundström; Anders Svenningsson; Rosanna Tortelli; Carla Tortorella; Alessandro Trentini; Maria Troiano; Martin R Turner; John C van Swieten; Mattias Vågberg; Marcel M Verbeek; Luisa M Villar; Pieter Jelle Visser; Anders Wallin; Andreas Weiss; Carsten Wikkelsø; Edward J Wild Journal: JAMA Neurol Date: 2019-09-01 Impact factor: 18.302
Authors: Robert T Naismith; Robert A Bermel; Christopher S Coffey; Andrew D Goodman; Janel Fedler; Marianne Kearney; Eric C Klawiter; Kunio Nakamura; Sridar Narayanan; Christopher Goebel; Jon Yankey; Elizabeth Klingner; Robert J Fox Journal: Neurology Date: 2020-12-02 Impact factor: 9.910
Authors: Jens Kuhle; Harald Kropshofer; Dieter A Haering; Uma Kundu; Rolf Meinert; Christian Barro; Frank Dahlke; Davorka Tomic; David Leppert; Ludwig Kappos Journal: Neurology Date: 2019-02-08 Impact factor: 9.910
Authors: Thomas E Williams; Katherine P Holdsworth; Jennifer M Nicholas; Arman Eshaghi; Theodora Katsanouli; Henrietta Wellington; Amanda Heslegrave; Henrik Zetterberg; Chris Frost; Jeremy Chataway Journal: Neurol Neuroimmunol Neuroinflamm Date: 2022-01-14
Authors: Alan J Thompson; William Carroll; Olga Ciccarelli; Giancarlo Comi; Anne Cross; Alexis Donnelly; Anthony Feinstein; Robert J Fox; Anne Helme; Reinhard Hohlfeld; Robert Hyde; Pamela Kanellis; Douglas Landsman; Catherine Lubetzki; Ruth Ann Marrie; Julia Morahan; Xavier Montalban; Bruno Musch; Sarah Rawlings; Marco Salvetti; Finn Sellebjerg; Caroline Sincock; Kathryn E Smith; Jon Strum; Paola Zaratin; Timothy Coetzee Journal: Mult Scler Date: 2021-12-01 Impact factor: 6.312
Authors: Rodolfo A Kölliker Frers; Matilde Otero-Losada; Tamara Kobiec; Lucas D Udovin; María Laura Aon Bertolino; María I Herrera; Francisco Capani Journal: Front Immunol Date: 2022-07-28 Impact factor: 8.786
Authors: Tamás Biernacki; Zsófia Kokas; Dániel Sandi; Judit Füvesi; Zsanett Fricska-Nagy; Péter Faragó; Tamás Zsigmond Kincses; Péter Klivényi; Krisztina Bencsik; László Vécsei Journal: Int J Mol Sci Date: 2022-03-21 Impact factor: 5.923